Special Issue

Possible Biomarkers in Oral Tumors and Their Clinical Significance

Message from the Guest Editor

Oral tumors are generally easy to access by visual inspection and palpation, and most definitive diagnoses are determined by the histopathological examination after biopsies. However, the diagnosis may often be difficult due to their histopathological varieties, especially in tumors originated from tooth germ, minor salivary gland, and mesenchyme, and so on. On the other hand, squamous cell carcinoma (SCC) is a typical malignancy in the oral cavity, the definitive diagnosis is comparatively easy because of their accessibility and characteristic histology. Although oral SCC is generally treated with surgery, radiotherapy, chemotherapy, immunotherapy, or their combination, the prognosis and the prediction of therapeutic effect are mainly determined by the histopathological degree of invasion and differentiation. Concerning the biomarker for oral SCC, serum SCC antigen is clinically applied but is not reliable as a sensitive biomarker. In this special issue, researchers who are a head and neck oncologist and has a wealth of basic data will discuss biomarkers that are expected to be applied clinically in relation to the diagnosis, recurrence, metastasis, or prognosis of oral tumors.

Guest Editor

Prof. Dr. Daisuke Uchida

Department of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon 791-0295, Ehime, Japan

Deadline for manuscript submissions

closed (30 November 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/136556

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

